Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 3, 2014, Pages 186-192

  Nagai, Minako ^a   Sho, Masayuki ^a   Satoi, Sohei ^b   Toyokawa, Hideyoshi ^b   Akahori, Takahiro ^a   Yanagimoto, Hiroaki ^b   Yamamoto, Tomohisa ^b   Hirooka, Satoshi ^b   Yamaki, So ^b   Kinoshita, Shoichi ^a   Nishiwada, Satoshi ^a   Ikeda, Naoya ^c   Kwon, A Hon ^b   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Complication; Maldigestion; NAFLD; Pancreaticoduodenectomy; Pancrelipase

Indexed keywords

LIPACREON; PANCRELIPASE; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DELAYED RELEASE FORMULATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DRUG CAPSULE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LABORATORY TEST; LIVER; MALE; MILD HEPATIC IMPAIRMENT; NONALCOHOLIC FATTY LIVER; NUTRITIONAL STATUS; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SPLEEN; TREATMENT RESPONSE; VERY ELDERLY; ADVERSE EFFECTS; CLINICAL TRIAL; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTOPERATIVE COMPLICATIONS; RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITIONAL STATUS; PANCREATICODUODENECTOMY; PANCRELIPASE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897002171     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.14     Document Type: Article

References (22)

1. Eckardt AJ, Klein F, Adler A, Veltzke-Schlieker W, Warnick P, Bahra M, et al. Management and outcomes of haemorrhage after pancreatogastrostomy versus pancreatojejunostomy. Br J Surg. 2011;98:1599-607.
2. Ahmad SA, Edwards MJ, Sutton JM, Grewal SS, Hanseman DJ, Maithel SK, et al. Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. Ann Surg. 2012;256:529-37.
3. Balzano G, Zerbi A, Capretti G, Rocchetti S, Capitanio V, Di Carlo V. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg. 2008;95:357-62.
4. de Wilde RF, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, et al. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg. 2012;99:404-10.
5. Kennedy EP, Brumbaugh J, Yeo CJ. Reconstruction following the pylorus preserving Whipple resection: PJ, HJ, and DJ. J Gastrointest Surg. 2010;14:408-15.
6. Braga M, Capretti G, Pecorelli N, Balzano G, Doglioni C, Ariotti R, et al. A prognostic score to predict major complications after pancreaticoduodenectomy. Ann Surg. 2011;254:702-7; discussion 7-8.
7. Kato H, Isaji S, Azumi Y, Kishiwada M, Hamada T, Mizuno S, et al. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system. J Hepatobiliary Pancreat Sci. 2010;17:296-304.
8. Nomura R, Ishizaki Y, Suzuki K, Kawasaki S. Development of hepatic steatosis after pancreatoduodenectomy. AJR Am J Roentgenol. 2007;189:1484-8.
9. Song SC, Choi SH, Choi DW, Heo JS, Kim WS, Kim MJ. Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy. World J Gastroenterol. 2011;17:3716-23.
10. Tanaka N, Horiuchi A, Yokoyama T, Kaneko G, Horigome N, Yamaura T, et al. Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. J Gastroenterol. 2011;46:758-68.
11. Yu HH, Shan YS, Lin PW. Effect of pancreaticoduodenectomy on the course of hepatic steatosis. World J Surg. 2010;34:2122-7.
12. van Galen KP, Stam F, van Oijen AH. [Hepatic encephalopathy following a Whipple operation]. Ned Tijdschr Geneeskd. 2009; 153:A463.
13. Dresler CM, Fortner JG, McDermott K, Bajorunas DR. Metabolic consequences of (regional) total pancreatectomy. Ann Surg. 1991;214:131-40.
14. Gubergrits N, Malecka-Panas E, Lehman GA, Vasileva G, Shen Y, Sander-Struckmeier S, et al. A6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Aliment Pharmacol Ther. 2011;33:1152-61.
15. Whitcomb DC, Lehman GA, Vasileva G, Malecka-Panas E, Gubergrits N, Shen Y, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gastroenterol. 2010;105:2276-86.
16. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-77.
17. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908-15.
18. Sho M, Tanaka T, Yamada T, Nomi T, Akahori T, Doh J, et al. Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Pancreat Sci. 2011;18:235-9; discussion 9-40.
19. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD- 9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450-6.
20. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G697-702.
21. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
22. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005; 2:46-53.